Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMH8VMP)

Drug Name

Emixustat Drug Info

Synonyms

EMIXUSTAT; UNII-02DZ1HBF0M; 1141777-14-1; 02DZ1HBF0M; Emixustat [USAN:INN]; (1R)-3-amino-1-[3-(cyclohexylmethoxy)phenyl]propan-1-ol; Incemixustat; ACU 4229; A3V; Emixustat (USAN); SCHEMBL966515; CHEMBL2107821; DTXSID50150665; WJIGGYYSZBWCGC-MRXNPFEDSA-N; ZINC59126886; AKOS032945088; CS-6177; DB12608; HY-19720; D10348; (r)-3-amino-1-(3-(cyclohexylmethoxy)phenyl)propan-1-ol; 3-Amino-1-[3-(cyclohexylmethoxy)phenyl]propan-1(R)-ol hydro -chloride

Indication

Disease Entry	ICD 11	Status	REF
Age-related macular degeneration	9B75.0	Phase 2/3	[1]
Proliferative diabetic retinopathy	9B71.01	Phase 2	[2]

Cross-matching ID

PubChem CID: 25221720
CAS Number: CAS 1141777-14-1
TTD Drug ID: DMH8VMP

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Retinal pigment epithelium protein (RPE65)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AAV2-hRPE65v2	DMJNSLU	Ocular disease	1F00.1Z	Phase 3	[3]
TgAAG76	DMNKLZM	Blindness	9D90	Phase 1/2	[4]
Leber's congenital amaurosis gene therapy	DMFHV9L	Leber congenital amaurosis	9B70	Phase 1/2	[5]
AAV-RPE65	DMAH6UJ	Leber congenital amaurosis	9B70	Phase 1/2	[6]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Retinal pigment epithelium protein (RPE65)	TTBOH16	RPE65_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01802866) Safety and Efficacy Assessment Treatment Trials of Emixustat Hydrochloride. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med. 2012 Feb 8;4(120):120ra15.
4	tgAAG76, an adeno-associated virus delivered gene therapy for the potential treatment of vision loss caused by RPE65 gene abnormalities. Curr Opin Mol Ther. 2010 Aug;12(4):471-7.
5	ClinicalTrials.gov (NCT00749957) Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis. U.S. National Institutes of Health.
6	Clinical pipeline report, company report or official report of MeiraGTx.